Antioxidant Properties of Bromocriptine, a Dopamine Agonist
- 1 March 1994
- journal article
- Published by Wiley in Journal of Neurochemistry
- Vol. 62 (3) , 1034-1038
- https://doi.org/10.1046/j.1471-4159.1994.62031034.x
Abstract
It has been suggested that free radicals may adversely influence the pathogenesis of Parkinson's disease. We conducted this study to determine whether bro‐mocriptine, an agent widely used for treating parkinsonism, possesses antioxidant effects. Bromocriptine scavenged superoxide produced from a superoxide generating system (hypoxanthine‐xanthine oxidase) by the spin‐trapping method using electron spin resonance. Bromocriptine had a strong scavenging effect on the 5,5‐dimethyl‐1‐pyrroline‐N‐oxide hydroxide signal produced from Fenton's reaction. Bromocriptine also attenuated the stable free radical diphenyl‐p‐picrylhydrazyl signal. This drug inhibited the autooxidation of rat brain homogenates in a dose‐dependent manner in vitro. Autooxidation of brain homogenates collected from rats treated with bromocriptine (2.5 mg/kg, i.p., daily for 3 days) was significantly reduced as compared with values in untreated rat homogenates. These observations suggest that bromocriptine is a free radical scavenger and a potent antioxidant.Keywords
This publication has 28 references indexed in Scilit:
- A simple fluorometric assay for lipoperoxide in blood plasmaPublished by Elsevier ,2004
- The possible role of iron in the etiopathology of parkinson's diseaseMovement Disorders, 1993
- Perturbations in cerebral oxygen radical formation and membrane order following vitamin E deficiencyBiochemical and Biophysical Research Communications, 1989
- A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia NigraJournal of Neurochemistry, 1989
- Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brainJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1988
- INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAINThe Lancet, 1987
- Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patientsNeuroscience Letters, 1986
- The effect of age on the activity and molecular properties of human brain monoamine oxidaseJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1980
- Interaction of Ergot Drugs with Central Monoamine SystemsPharmacology, 1978
- BROMOCRIPTINE AND LEVODOPA (WITH OR WITHOUT CARBIDOPA) IN PARKINSONISMThe Lancet, 1976